Outslickd Posted - 4 days ago

$LQDA constantly a magnet to the whole numbers.

Preacherclint10 Posted - 4 days ago

$LQDA scam-a-deia

basedman Posted - 5 days ago

$LQDA still holding strong. big dumb to sell at these levels. May 2025 ultimate catalyst but lets see what this new admin does to the FDA…perhaps a quicker move once these muzzle this scumbag organization.

ra_VEEN Posted - 1 week ago

$LQDA slow bleed til May

NEWBIGTECH Posted - 1 week ago

$CHGG $LQDA $HOOD $FEMY $LUCD

grampslol Posted - 1 week ago

$UTHR sinking AH $LQDA leak ? $MNKD

MayorofMNKD Posted - 1 week ago

$LQDA …down again??

Thestocktraderhubzee Posted - 1 week ago

WATCHLIST NOV 14 2024. $LUCD Needham Reiterates Buy on Lucid Diagnostics, Maintains $2.5 Price Target $LQDA Needham Reiterates Buy on Liquidia, Maintains $19 Price Target $HOOD Deutsche Bank Maintains Buy on Robinhood Markets, Raises Price Target to $35 $CHGG Piper Sandler Maintains Underweight on Chegg, Lowers Price Target to $1.5 $FEMY Chardan Capital Maintains Buy on Femasys, Lowers Price Target to $8

d_risk Posted - 1 week ago

$LQDA - Liquidia - 10Q - Updated Risk Factors Multiple lawsuits from United Therapeutics, dependency on third-party FDA compliance, and restrictive financing covenants pose significant risks, alongside heightened competition and financial uncertainties. #Risk @Liquidia_Corp https://d-risk.ai/LQDA/10-Q/2024-11-13

evetsoloccip Posted - 1 week ago

$MNKD $LQDA had a nice ER

DonCorleone77 Posted - 1 week ago

$LQDA Liquidia reports Q3 EPS (30c), consensus (37c) Reports Q3 revenue $4.4M, consensus $4.19M. Cash and cash equivalents totaled $204.4M as of September 30, compared to $83.6M as of December 31, 2023. Roger Jeffs, Liquidia's CEO, said: "This quarter we achieved our goal of adding pulmonary hypertension associated with interstitial lung disease to the indication statement for YUTREPIA. While the FDA decision to grant three-year exclusivity to TYVASO DPI, which will expire on May 23, 2025, currently gates our launch, we will exhaust every effort to bring YUTREPIA to market sooner, as evidenced by our litigation against the FDA to contest what we believe to be the improper grant of exclusivity to TYVASO DPI. In the interim, we will use this pre-launch period to further advance knowledge of the clinical profile of YUTREPIA in PH-ILD patients through our ASCENT study, where we hope to show YUTREPIA's clear advantages related to the tolerability, titratability and durability in this underserved patient population."

HamPlanet Posted - 2 weeks ago

$LQDA Imagine hating patient choice because you think it helps your portfolio

ra_VEEN Posted - 2 weeks ago

$LQDA why we getting cucked here all of a sudden

Outslickd Posted - 3 weeks ago

$LQDA $11 magnet

ItzaFugazi Posted - 10/30/24

$MNKD Well the results certainly do make me laugh. Not that I am at all disappointed in results but how outrageous the claims of analysts around yutrepia promote the diatribe. They expect yutrepia to garnish over 1 billion in sales shortly after approval. $UTHR in total Tyvaso sales is just north of 1.6 billion and I highly doubt $LQDA will come close to this metric with a less efficient and inferior product. The future growth lies with IPF and IPP a huge market and if approved for Tyvaso DPI, $LQDA will not be allowed in for minimum 7-10 years.

insiderbuyingselling Posted - 10/29/24

$LQDA new insider selling: 459 shares. http://insiderbuyingselling.com/?t=LQDA

danshep55 Posted - 10/28/24

$lqda Jan 12.50 calls . Needs strong 11.4 base

LuigiMoro Posted - 10/25/24

@essiepaul $LQDA I also bought yesterday 500 shares. Changed my mind, since the Insider selling is standard procedure. Maybe I will add more if it goes lower. The technology is great. GL

essiepaul Posted - 10/24/24

$LQDA added 11.02. Seems to be de-risked but who knows what other bs $UTHR attorneys could pull out of their behinds

LuigiMoro Posted - 4 weeks ago

$LQDA I wanted to buy in but since Insiders selling like hell. I am not touching that shit....

insiderbuyingselling Posted - 1 month ago

$LQDA new insider selling: 2526 shares. http://insiderbuyingselling.com/?t=LQDA

swingingtech Posted - 1 month ago

$ULTA $LCID $LQDA https://wallstreetwaves.com/highlights-of-thursdays-significant-options-activity-ulta-lcid-lqda/

andras1 Posted - 1 month ago

$LQDA From Scotiabank: Liquidia – Sector Outperform; $30.00 target price. As Liquidia’s legal battle with competitor United Therapeutics Corporation (Tyvaso) comes to a close, we expect Yutrepia’s impending launch (May 2025) to take center stage. Although pulmonary arterial hypertension (PAH) is a crowded market, treprostinil use is increasing and our KOLs note that Yutrepia could differentiate on tolerability, with the potential to take market share from Tyvaso. We see significant opportunity in pulmonary hypertension (PH) associated with interstitial lung disease (ILD; together, PH-ILD), a new and growing market, where we estimate Yutrepia could generate >$1 billion in sales with a conservative patient penetration.

insiderbuyingselling Posted - 1 month ago

$LQDA new insider selling: 1146 shares. http://insiderbuyingselling.com/?t=LQDA

ItzaFugazi Posted - 1 month ago

@JumboMike $LQDA followers are painting this as a huge win. I do not see it this way. Conditional approval occurred 11/21, now they will get approval around 6/25. I dont call a 3 year 6 month delay a win since UTHR has consolidating market share with a superior product by all metrics. UTHR only impetus was delay until IPF studies are completed. It appears they have been successful. Lastly there is a criminal case pending against LQDA which during discovery has showed merit. Ironicall, if successful LQDA may be paying hefty royalty if they lose this case.

Preacherclint10 Posted - 1 month ago

$LQDA ponzi scam !

DaBullRunner Posted - 1 month ago

$LQDA alerted this under $3 actually and looking good so far RZLV is an AI company that is fairly unknown but will soon gain a lot of attention and traction imo I believe RZLV will be in the double digits in due time

basedman Posted - 1 month ago

$LQDA no more road blocks to launch. Either in May 25 or earlier if $LQDA wins the suit. Just buckle up and dont sell until then

FuriousGeorge42 Posted - 1 month ago

$LQDA 😂 where are all my MNKD trolls today? Omg you guys gotta be so mad you’re gonna blow a vein. Hahaha let’s go!!

G101SPM Posted - 1 month ago

$LQDA $11.16 +1.15. DAC (4) $12.20. EXIT $30.00 - Legacy holding (long term). BRIEF: Co announced that the United States Supreme Court has rejected United Therapeutics' (UTHR) petition for a writ of certiorari, which requested permission to appeal prior decisions which found that all claims of U.S. Patent No. 10,716,793 (‘793 Patent) are unpatentable due to prior art. As a result, the decision by the Patent Trial and Appeal Board (PTAB) in July 2022, which was affirmed by the U.S. Court of Appeals for the Federal Circuit (Federal Circuit) in December 2023, is now final and not subject to further appeal.